-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Vj3HnIS7l5U+M8xQcF11jV7PvIozn5rm/ainHXQGWC7RZuva3dTHBxNLJyxTZpFh D+RdqZH9Bq490E9ZIt/6Tw== 0000898430-98-000735.txt : 19980302 0000898430-98-000735.hdr.sgml : 19980302 ACCESSION NUMBER: 0000898430-98-000735 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 19980227 SROS: NASD GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P ET AL GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF PARTNERS L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-44877 FILM NUMBER: 98552903 BUSINESS ADDRESS: STREET 1: 420 CHIPETA WAY SUITE 240 CITY: SALT LAKE CITY STATE: UT ZIP: 84108-1256 BUSINESS PHONE: 8015834939 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P ET AL CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-288-2395 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13D/A 1 AMENDMENT #2 TO SCHEDULE 13-D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 --------------- SCHEDULE 13D (RULE 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)/1/ NPS PHARMACEUTICALS, INC. ------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 62936 P 103 ----------- (CUSIP Number) Hope Flack BVF Partners L.P. 333 West Wacker Drive, Suite 1600 Chicago, Illinois 60606 (312) 263-7777 -------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 30, 1998 ---------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 7 Pages) - --------------------- /1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 Page 2 of 7 Pages - ----------------------------- ------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Biotechnology Value Fund, L.P. - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [_] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] - -------------------------------------------------------------------------------- 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7. SOLE VOTING POWER NUMBER OF -0- SHARES ------------------------------------------------------------------ BENEFICIALLY 8. SHARED VOTING POWER OWNED BY 569,900 REPORTING ------------------------------------------------------------------ PERSON 9. SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------ 10. SHARED DISPOSITIVE POWER 569,900 - -------------------------------------------------------------------------------- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 569,900 - -------------------------------------------------------------------------------- 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* [_] - -------------------------------------------------------------------------------- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.7% - -------------------------------------------------------------------------------- 14. TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! SCHEDULE 13D - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 Page 3 of 7 Pages - ----------------------------- ------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF Partners L.P. - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [_] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. SOURCE OF FUNDS* OO - -------------------------------------------------------------------------------- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] - -------------------------------------------------------------------------------- 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7. SOLE VOTING POWER NUMBER OF -0- SHARES ------------------------------------------------------------------ BENEFICIALLY 8. SHARED VOTING POWER OWNED BY 1,141,800 REPORTING ------------------------------------------------------------------ PERSON 9. SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------ 10. SHARED DISPOSITIVE POWER 1,141,800 - -------------------------------------------------------------------------------- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,141,800 - -------------------------------------------------------------------------------- 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* [_] - -------------------------------------------------------------------------------- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 9.5% - -------------------------------------------------------------------------------- 14. TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! SCHEDULE 13D - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 Page 4 of 7 Pages - ----------------------------- ------------------------- - -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF Inc. - -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [_] - -------------------------------------------------------------------------------- 3. SEC USE ONLY - -------------------------------------------------------------------------------- 4. SOURCE OF FUNDS* WC, OO - -------------------------------------------------------------------------------- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] - -------------------------------------------------------------------------------- 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7. SOLE VOTING POWER NUMBER OF -0- SHARES ------------------------------------------------------------------ BENEFICIALLY 8. SHARED VOTING POWER OWNED BY 1,141,800 REPORTING ------------------------------------------------------------------ PERSON 9. SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------ 10. SHARED DISPOSITIVE POWER 1,141,800 - -------------------------------------------------------------------------------- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,141,800 - -------------------------------------------------------------------------------- 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* [_] - -------------------------------------------------------------------------------- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 9.5% - -------------------------------------------------------------------------------- 14. TYPE OF REPORTING PERSON* IA, CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 SCHEDULE 13D Page 5 of 7 Pages - ----------------------------- ------------------------- This Amendment No. 2 (this "Amendment") relates to the Statement on Schedule 13D, dated April 25, 1997, as amended by Amendment No. 1, dated December 1, 1997 (as so amended, the "Statement"), filed with the Securities and Exchange Commission on behalf of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership ("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together with BVF and Partners, the "Reporting Persons") with respect to the Common Stock, par value $0.001 per share (the "Stock"), of NPS Pharmaceuticals, Inc., a Delaware corporation ("NPS"). The principal executive office of NPS is located at 420 Chipeta Way, Suite 240, Salt Lake City, UT 84108-1256. Item 3 is hereby amended to read in its entirety as follows: ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Since December 26, 1997, Partners, in its capacity as general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 40,500 shares of the Stock for an aggregate consideration of $310,562.50, utilizing funds provided by BVF from its working capital pursuant to the terms of its limited partnership agreement with Partners. In addition, Partners, in its capacity as investment manager with respect to certain managed accounts, has purchased on behalf of such managed accounts an aggregate number of 102,400 shares of the Stock for an aggregate consideration of $792,514.32 utilizing funds under management by Partners pursuant to investment management agreements between Partners and such managed accounts. Item 5 is hereby amended to read in its entirety as follows: ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) BVF beneficially owns 569,900 shares of the Stock, Partners beneficially owns 1,141,800 shares of the Stock, and BVF Inc. beneficially owns 1,141,800 shares of the Stock, approximately 4.7%, 9.5% and 9.5%, respectively, of the aggregate number of shares outstanding as of September 30, 1997 (as reported in NPS's most recent quarterly statement on Form 10-Q). (b) BVF shares voting and dispositive power over the 569,900 shares of the Stock it beneficially owns with Partners. Partners and BVF Inc. share voting and dispositive power over the 1,141,800 shares of the Stock they beneficially own with, in addition to BVF, the managed accounts on whose behalf Partners, as investment manager, purchased such shares. The managed accounts on whose behalf Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited liability company ("ILL10"), Palamundo, L.D.C., a limited duration company organized under the laws of the Cayman Islands ("Palamundo"), ZPG - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 SCHEDULE 13D Page 6 of 7 Pages - ----------------------------- ------------------------- Securities, L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10, Palamundo, ZPG and BVF Ltd. are collectively referred to herein as the "Accounts." The Accounts specialize in holding biotechnology stocks for investment purposes and the business address of each is c/o BVF Partners L.P., 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606. (c) Exhibit B attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the past 60 days. All such transactions were made for cash in open market, over-the-counter transactions. No other transactions in the Stock have been effected by the Reporting Persons during the past 60 days. (d) The Accounts are entitled to receive dividends and any sale proceeds with respect to the Stock in proportion to their respective ownership interests therein. Item 7 is hereby amended to read in its entirety as follows: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Agreement Regarding Joint Filing Exhibit B - Transactions in the Stock by the Reporting Persons during the last 60 days. - ----------------------------- ------------------------- CUSIP NO. 62936 P 103 SCHEDULE 13D Page 7 of 7 Pages - ----------------------------- ------------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 27, 1998 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President EX-99.A 2 AGREEMENT REGARDING JOINT FILING EXHIBIT A AGREEMENT REGARDING JOINT FILING -------------------------------- The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them. Dated: February 27, 1998 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ------------------- Mark N. Lampert President EX-99.B 3 TRANSACTIONS IN THE STOCK EXHIBIT B TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS -------------------------------------------------- DURING THE LAST 60 DAYS -----------------------
Settlement By For the Quantity Price Type of Trade Broker Date ----------- Account of -------- per ------------- ------ - ---------- ----------- Share --------- ====================================================================================== 12/26/97 Partners BVF 26,500 $7.6250 Purchase OPCO - -------------------------------------------------------------------------------------- 12/26/97 Partners ILL10 3,750 $7.6250 Purchase OPCO - -------------------------------------------------------------------------------------- 12/26/97 Partners PAL 2,250 $7.6250 Purchase OPCO - -------------------------------------------------------------------------------------- 12/26/97 Partners ZPG 2,000 $7.6250 Purchase OPCO - -------------------------------------------------------------------------------------- 12/26/97 Partners BVF Ltd. 15,500 $7.6250 Purchase OPCO - -------------------------------------------------------------------------------------- 01/06/98 Partners BVF Ltd. 4,600 $7.5761 Purchase INET - -------------------------------------------------------------------------------------- 01/08/98 Partners BVF Ltd. 3,800 $7.6447 Purchase INET - -------------------------------------------------------------------------------------- 01/20/98 Partners BVF Ltd. 4,000 $8.0000 Purchase INET - -------------------------------------------------------------------------------------- 01/21/98 Partners BVF Ltd. 50,000 $7.7750 Purchase VECT - -------------------------------------------------------------------------------------- 01/21/98 Partners BVF Ltd. 3,500 $7.8214 Purchase INET - -------------------------------------------------------------------------------------- 01/29/98 Partners BVF Ltd. 1,000 $7.7500 Purchase INET - -------------------------------------------------------------------------------------- 01/30/98 Partners BVF 14,000 $7.7500 Purchase VECT - -------------------------------------------------------------------------------------- 01/30/98 Partners PAL 2,000 $7.7500 Purchase VECT - -------------------------------------------------------------------------------------- 01/30/98 Partners BVF Ltd. 10,000 $7.7500 Purchase VECT - --------------------------------------------------------------------------------------
OPCO = Oppenheimer & Co., Inc. INET = Instinet VECT = Vector Securities -----END PRIVACY-ENHANCED MESSAGE-----